Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects
Retrieved on:
Wednesday, October 5, 2022
Mental Health, Nursing, Seniors, Neurology, Clinical Trials, Biotechnology, Managed Care, Pharmaceutical, Consumer, Health, U.S. Securities and Exchange Commission, Caregiver, Drug Quality and Security Act, Review, Lithium carbonate, Post-traumatic stress disorder, Nostrand Avenue station (IND Fulton Street Line), MAD, MDD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Major depressive disorder, Patient, Securities Act of 1933, Nasdaq, Bipolar disorder, Dementia, Lithium, University, Food, Nature, Adult, Securities Exchange Act of 1934, Safety, Lithium toxicity, IIA, Clinical trial, Plasma, Phase, Forward-looking statement, FDA, PTSD, Risk, Pharmaceutical industry
Alzamend is also pursuing AL001 for the treatment of bipolar disorder, MDD and PTSD.
Key Points:
- Alzamend is also pursuing AL001 for the treatment of bipolar disorder, MDD and PTSD.
- As the safety and tolerability of AL001 would need to be tested in healthy and elderly adults before Alzamend could initiate later-stage testing of AL001 for bipolar disorder, MDD and PTSD, the addition of healthy and elderly adults to the on-going AL001-02 clinical trial would expedite the timing of further clinical trials.
- Alzamend will test AL001 in four healthy adult and elderly adult cohorts of eight subjects under MAD conditions.
- AL001 has the potential to deliver benefits of marketed lithium carbonate while mitigating or avoiding current toxicities associated with lithium.